Naslov
Ethinylestradiol/chlormadinone acetate- A contraceptive with additional noncontraceptive benefits.

Autori
Pavičić Baldani, Dinka ; Škrgatić, Lana ; Šprem Goldštajn, Marina ; Kasum, Miro, Orešković, Slavko

Izvornik
Gynaecologia et perinatologia (1330-0091) 24 (2015), 4; 164-173

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni

Ključne riječi
hormonal contraception, CMA, EE

Sažetak
The fundamental reason for using oral hormonal contraception is protection from unwanted pregnancies and their most unwanted consequences, artificial abortions. Countries reporting a low rate of effective contraceptive methods usage, like hormonal contraception, notice a high rate of deliberately induced abortions. The main reasons for low rate of hormonal contraceptives use have been recognized and they include wrong perception and misinformation’s amongst women, incorrect information’s given by health care providers and insufficient choice of contraceptive that allows individualization of the therapy. Current expectations from contraception are not just high contraceptive efficacy, but also the improvement of the symptoms associated with menstrual cycle, and all this, with minimal health risks. It is well known that different hormonal contraceptives, in spite of the same therapeutic indications have different individual tolerance and different non-contraceptive benefits. Therefore, the variety of hormonal contraceptives of different dose and composition is necessary to allow individual selection of therapy. The oral hormonal contraceptive with 0, 03 mg of ethinyl estradiol (EE)/2 mg chlormadinone acetate (CMA) is a low- dose oral hormonal contraceptive with antiandrogenic effect. It is proved to be safe and effective oral hormonal contraceptive with a corrected Pearl Index of 0, 04 and positive effects on indicators of cardiovascular risk, as well as with very low risk of occurrence of venous thromboembolism of 2, 07/10 000 women per year. Because of its proven antiandrogenic action it demonstrates a beneficial effect on the skin and hair in reducing acne, seborrhea and hirsutism. The ability of this contraceptive to significantly reduce monthly bleeding and pain indicates its potential use in the treatment of anemia and dysmenorrhea. The combination of these benefits and the absence of weight gain, as well as positive psychotropic action with the absence of negative effects on libido contribute to high compliance and a low discontinuation rate of the treatment.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA